Claire F. Verschraegen

Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies

Yi-Zhou Jiang, Ding Ma, Chen Suo et al. · Cancer Cell · 2019 · 1.1K citations · Full text

Life Sciences, Molecular Biology, Oncology +16

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

Steven O’Day, Michele Maio, Vanna Chiarion‐Sileni et al. · Annals of Oncology · 2010 · 510 citations

Pharmacy, Oncology, Pharmacotherapy +14

Incidence and Survival Rates for Female Malignant Germ Cell Tumors

Harriet O. Smith, Marianne Berwick, Claire F. Verschraegen et al. · Obstetrics and Gynecology · 2006 · 380 citations

Medicine, Oncology, Cancer Epidemiology +15

Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

Yi-Zhou Jiang, Yin Liu, Yi Xiao et al. · Cell Research · 2020 · 314 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.

Andrzej P. Kudelka, Damrong Tresukosol, Creighton L. Edwards et al. · Journal of Clinical Oncology · 1996 · 254 citations

Medicine, Oncology, Pharmacology +17